Search Results - "HAMEL, Lucie"

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer by Audet-Walsh, Étienne, Dufour, Catherine R, Yee, Tracey, Zouanat, Fatima Z, Yan, Ming, Kalloghlian, Georges, Vernier, Mathieu, Caron, Maxime, Bourque, Guillaume, Scarlata, Eleonora, Hamel, Lucie, Brimo, Fadi, Aprikian, Armen G, Lapointe, Jacques, Chevalier, Simone, Giguère, Vincent

“…Androgen receptor (AR) signaling reprograms cellular metabolism to support prostate cancer (PCa) growth and survival. Another key regulator of cellular…”
Get full text

Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients by Bramhecha, Yogesh M., Guérard, Karl-Philippe, Audet-Walsh, Étienne, Rouzbeh, Shaghayegh, Kassem, Ola, Pernet, Erwan, Scarlata, Eleonora, Hamel, Lucie, Brimo, Fadi, Divangahi, Maziar, Aprikian, Armen G., Chevalier, Simone, Giguère, Vincent, Lapointe, Jacques

“…Prostate cancer (PCa) metastases are highly enriched with genomic alterations including a gain at the 16p13.3 locus, recently shown to be associated with…”
Get full text

Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention by Bramhecha, Yogesh M, Guérard, Karl-Philippe, Rouzbeh, Shaghayegh, Scarlata, Eleonora, Brimo, Fadi, Chevalier, Simone, Hamel, Lucie, Dragomir, Alice, Aprikian, Armen G, Lapointe, Jacques

“…Identifying tumors with high metastatic potential is key to improving the clinical management of prostate cancer. Recently, we characterized a chromosome…”
Get full text

Improving ultrasound-based prostate volume estimation by Aprikian, Saro, Luz, Murilo, Brimo, Fadi, Scarlata, Eleonora, Hamel, Lucie, Cury, Fabio L, Tanguay, Simon, Aprikian, Armen G, Kassouf, Wassim, Chevalier, Simone

“…To define a new coefficient to be used in the formula (Volume = L x H x W x Coefficient) that better estimates prostate volume using dimensions of fresh…”
Get full text

Liquid biopsy‐based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer by Derderian, Seta, Vesval, Quentin, Wissing, Michel D., Hamel, Lucie, Côté, Nathalie, Vanhuyse, Marie, Ferrario, Cristiano, Bladou, Franck, Aprikian, Armen, Chevalier, Simone

“…Prostate cancer (PCa) clinical heterogeneity underscores tumor heterogeneity, which may be best defined by cell subtypes. To test if cell subtypes contributing…”
Get full text

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression by Derderian, Seta, Benidir, Tarik, Scarlata, Eleonora, Altaylouni, Turki, Hamel, Lucie, Zouanat, Fatima Zahra, Brimo, Fadi, Aprikian, Armen, Chevalier, Simone

“…The androgen receptor (AR) plays a crucial role in the development and homeostasis of the prostate and is a key therapeutic target in prostate cancer (PCa)…”
Get full text

The Fer Tyrosine Kinase Cooperates with Interleukin-6 to Activate Signal Transducer and Activator of Transcription 3 and Promote Human Prostate Cancer Cell Growth by Zoubeidi, Amina, Rocha, Joice, Zouanat, Fatima Z, Hamel, Lucie, Scarlata, Eleonora, Aprikian, Armen G, Chevalier, Simone

“…Androgen withdrawal is the most effective form of systemic therapy for men with advanced prostate cancer. Unfortunately, androgen-independent progression is…”
Get full text

Abstract CC06-01: Identifying therapeutic options for patients with advanced prostate cancer through genes in liquid biopsies by Derderian, Seta, Jarry, Edouard, Santos, Arynne, Amaravadi, Mohanachary, Vesval, Quentin, Hamel, Lucie, Cote, Nathalie, Vanhuyse, Marie, Aprikian, Armen, Chevalier, Simone

“…Prostate cancer (PCa) is curable in most men but becomes lethal for patients with metastases at diagnosis and those who experience biochemical recurrence (BCR)…”
Get full text

Asporin is a stromally expressed marker associated with prostate cancer progression by Rochette, Annie, Boufaied, Nadia, Scarlata, Eleonora, Hamel, Lucie, Brimo, Fadi, Whitaker, Hayley C, Ramos-Montoya, Antonio, Neal, David E, Dragomir, Alice, Aprikian, Armen, Chevalier, Simone, Thomson, Axel A

“…Background: Prostate cancer shows considerable heterogeneity in disease progression and we propose that markers expressed in tumour stroma may be reliable…”
Get full text

A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients by Ebrahimizadeh, Walead, Guérard, Karl-Philippe, Rouzbeh, Shaghayegh, Scarlata, Eleonora, Brimo, Fadi, Patel, Palak G., Jamaspishvili, Tamara, Hamel, Lucie, Aprikian, Armen G., Lee, Anna Y., Berman, David M., Bartlett, John M. S., Chevalier, Simone, Lapointe, Jacques

“…Background Distinguishing between true indolent and potentially life-threatening prostate cancer is challenging in tumours displaying clinicopathologic…”
Get full text

PD65-12 THE ANDROGEN RECEPTOR BECOMES A NOVEL PREDICTIVE BIOMARKER OF PROSTATE CANCER PROGRESSION WHEN POST TRANSLATIONALLY ACTIVATED BY THE FER KINASE ON TYROSINE 223 by Altaylouni, Turki, Zouanat, Fatima, Scarlata, Eleonora, Benidir, Tarik, Hamel, Lucie, Brimo, Fadi, Bégin, Louis, Aprikian, Armen, Chevalier, Simone

Get full text

The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy by Bramhecha, Yogesh M., Rouzbeh, Shaghayegh, Guérard, Karl-Philippe, Scarlata, Eleonora, Brimo, Fadi, Chevalier, Simone, Hamel, Lucie, Aprikian, Armen G., Lapointe, Jacques

“…Prostate cancer is a clinically heterogeneous disease and accurately risk-stratifying patients is a key clinical challenge. We hypothesized that the concurrent…”
Get full text

CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis by Dankner, Matthew, Ouellet, Véronique, Communal, Laudine, Schmitt, Estelle, Perkins, Dru, Annis, Matthew G., Barrès, Véronique, Caron, Christine, Mes-Masson, Anne-Marie, Saad, Fred, Siegel, Peter M.

“…Prostate cancer (PC) commonly metastasizes to the bone, resulting in pathologic fractures and poor prognosis. CCN3/nephroblastoma overexpressed is a secreted…”
Get full text

Abstract 3665: Stratifying prostate cancer patients through circulating genes related to prostate cell subtypes, drug targets, and therapeutic resistance by Derderian, Seta, Jarry, Edouard, Santos, Arynne, Amaravadi, Mohanachary, Vesval, Quentin, Hamel, Lucie, Sanchez-Salas, Raphael, Rompré-Brodeur, Alexis, Kassouf, Wassim, Rajan, Raghu, Duclos, Marie, Brimo, Fadi, Aprikian, Armen, Chevalier, Simone

“…Stratification remains an obstacle for the optimal treatment of prostate cancer (PCa) patients throughout the treatment trajectory. Targeting the androgen…”
Get full text

The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer by Rocha, Joice, Zouanat, Fatima Z., Zoubeidi, Amina, Hamel, Lucie, Benidir, Tarik, Scarlata, Eleonora, Brimo, Fadi, Aprikian, Armen, Chevalier, Simone

“…•The Fer kinase permits cells to adapt to castration-resistance in prostate cancer.•Mechanistically, Fer allows cross-talk of the IL-6/pSTAT3 pathway with AR…”
Get full text

Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate by Chevalier, Simone, Anidjar, Maurice, Scarlata, Eleonora, Hamel, Lucie, Scherz, Avigdor, Ficheux, Hervé, Borenstein, Nicolas, Fiette, Laurence, Elhilali, Mostafa

“…Vascular targeted photodynamic therapy with WST09 shows promise for recurrent prostate cancer after radiation but hydrophobicity in aqueous solutions limited…”
Get more information

Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model by Chevalier, Simone, Cury, Fabio L, Scarlata, Eleonora, El-Zayat, Ehab, Hamel, Lucie, Rocha, Joice, Zouanat, Fatima Z, Moussa, Sabri, Scherz, Avigdor, Elhilali, Mostafa, Anidjar, Maurice

“…Vascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is in phase III clinical trials of an interstitial transperineal approach for focal therapy…”
Get more information

Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men by Anidjar, Maurice, Scarlata, Eleonora, Cury, Fabio L., Rocha, Joice, Hamel, Lucie, Luz, Murilo, Chevalier, Simone

“…BACKGROUND Rodent models are often suboptimal for translational research on human prostate cancer (PCa). To better fill the gap with human, we refined the…”
Get full text

Refining the Orthotopic Dog Prostate Cancer (DPC)-I Model to Better Bridge the Gap Between Rodents and Men by ANIDJAR, Maurice, SCARLATA, Eleonora, CURY, Fabio L, ROCHA, Joice, HAMEL, Lucie, LUZ, Murilo, CHEVALIER, Simone

Get full text

Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank by Brimo, Fadi, Aprikian, Armen, Latour, Mathieu, Têtu, Bernard, Doueik, Alexandre, Scarlata, Eleonora, Hamel, Lucie, McKercher, Ginette, Saad, Fred, Lacombe, Louis, Carmel, Michel, Chevalier, Simone

“…Well-characterized, high-quality fresh-frozen prostate tissue is required for prostate cancer research. As part of the PROCURE Prostate Cancer Biobank launched…”
Get more information